Trial Profile
A 104-week, Randomized, Open-labeled, Active-control Study on Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cilostazol (Primary) ; Aspirin
- Indications Cognition disorders; Vascular dementia
- Focus Therapeutic Use
- 10 Jun 2013 New source identified and integrated: ClinicalTrials.gov record NCT01872858 (Huashan Hospital).
- 10 Jun 2013 New source identified and integrated: ClinicalTrials.gov record NCT01872858 (Huashan Hospital).
- 10 Jun 2013 New trial record